A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Takeda
- 29 Jun 2018 Planned End Date changed from 31 Aug 2021 to 30 Apr 2019.
- 29 Jun 2018 Planned primary completion date changed from 30 Sep 2020 to 30 Apr 2019.
- 14 Nov 2017 New trial record